

FDA panel has tie vote on new type 1 diabetes drug

January 18 2019



(HealthDay)—A U.S. Food and Drug Administration advisory panel

vote on whether to recommend approval of the first oral medication for type 1 diabetes ended in an 8-8 tie Thursday.

Despite that result, the FDA is expected to decide by the end of March whether the drug—sotagliflozin, brand name Zynquista—should be made available in the United States, *The New York Times* reported. The drug, used along with insulin, is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels.

Some of the advisory panel members voted against Zynquista because it carries an increased risk for diabetic ketoacidosis, *The Times* reported.

Drug makers Sanofi and Lexicon Pharmaceuticals said they will continue to work with the FDA through the [review process](#) for the [drug](#).

More information: [The New York Times Article](#)

Copyright © 2019 [HealthDay](#). All rights reserved.

Citation: FDA panel has tie vote on new type 1 diabetes drug (2019, January 18) retrieved 4 February 2024 from <https://medicalxpress.com/news/2019-01-fda-panel-vote-diabetes-drug.html>

| |
|--|
| <p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p> |
|--|